Abstract
Since clinical outcome of patients with metastatic RCC (mRCC) is poor, identification of prognostic and therapeutic markers is essential for better treatment options, but limited because metastases (MS) are generally not treated surgically. Based on a specific 1318 nm-laser resection, multiple pulmonary MS (pMS) from mRCC patients were collected and used for survivin (SVV) and XIAP expression analyses.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
